Drugs / OH2
OH2
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05954091 | Sep 2025 → Jul 2027 expected | cancer | Binhui Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05698459 | May 2023 → Aug 2025 overdue | liver cancer | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04755543 | Jun 2019 → Jun 2021 | digestive system neoplasm | Taizhou HoudeAoke Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07382531 | Sep 2023 → Dec 2027 expected | cancer | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05232136 | Jul 2022 → Jun 2025 overdue | urinary bladder carcinoma | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05235074 | Nov 2021 → Jun 2026 overdue | central nervous system neoplasm | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04637698 | Feb 2021 → May 2023 | malignant pancreatic neoplasm | Binhui Biopharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04616443 | Dec 2020 → Nov 2025 overdue | melanoma | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03866525 | Apr 2019 → Aug 2025 overdue | digestive system cancer | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04386967 | Nov 2018 → Mar 2026 overdue | cancer, melanoma | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05648006 | Oct 2023 → Apr 2024 | colorectal carcinoma | Binhui Biopharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05248789 | May 2022 → Oct 2024 | urinary bladder carcinoma | Binhui Biopharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT05868707 | Mar 2023 → Mar 2026 overdue | melanoma | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07854522 | Oct 2026 → Sep 2029 expected | melanoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OH2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05698459 ↗ |
| Known as | Recombinant Oncolytic HSV2 | “Recombinant Oncolytic HSV2（OH2）Therapeutic Injecta(Vero Cell) for Human Use(rHSV2hGM-CSF)” NCT05648006 ↗ |
| Known as | rHSV2hGM-CSF | “Recombinant Oncolytic HSV2（OH2）Therapeutic Injecta(Vero Cell) for Human Use(rHSV2hGM-CSF)” NCT05648006 ↗ |
| Modality | Other / unclassified | “OH2 (an oncolytic virus)” NCT04755543 ↗ |
| Route | Other | “administered by intratumoral injection of EUS-FNA” NCT04637698 ↗ |